EM · Antimicrobial stewardship in the emergency department
Antimicrobial stewardship in the emergency department — right drug, dose, route and duration, syndromic empirical therapy, de-escalation and resistance
Also known as Antimicrobial stewardship · Antibiotic stewardship · Antimicrobial stewardship programme · Right drug dose duration route · Empirical antibiotic therapy · De-escalation · Syndromic empirical therapy · Antibiotic resistance · MRSA · VRE · ESBL · CPE · Carbapenem-resistant Enterobacterales · Beers criteria · STOPP START · Drug-bug mismatch
Antimicrobial stewardship in the emergency department — the coordinated set of interventions to optimise antimicrobial use, captured in the principle of the right drug, the right dose, the right route and the right duration, with de-escalation when culture and susceptibility data return; the syndromic empirical therapy matrix for the front door — sepsis (ceftriaxone 2 g), community-acquired bacterial meningitis (ceftriaxone plus vancomycin, plus ampicillin if Listeria is a risk), community-acquired pneumonia (ceftriaxone plus azithromycin), cellulitis (flucloxacillin 2 g) and urinary tract infection (trimethoprim or nitrofurantoin); the de-escalation rule of narrow-to-spectrum, stop-when-non-infectious and switch-to-oral when stable; the resistance patterns (MRSA, VRE, ESBL, CPE) and their treatment implications; the Beers 2023 and STOPP/START criteria for the elderly patient; and the regional stewardship frameworks (Australian Therapeutic Guidelines — Antibiotic and ACSQHC, NICE NG15, IDSA/SHEA and the CDC Core Elements). ACEM-primary, globally tagged.
Practise this topic
On this page
Study tools
Your progress
Saved on this device.
Target exams
Red flags
- Antibiotics within one hour of recognising sepsis or septic shock — every hour of delay in effective therapy is an independent mortality multiplier (Kumar, Seymour); the Surviving Sepsis Campaign Hour-1 bundle is non-negotiable
- Send cultures before the antibiotic dose when it can be done without delaying therapy beyond an hour — but never delay the antibiotic to wait for cultures in septic shock
- Ceftriaxone does not cover Listeria, MRSA, ESBL-producing Enterobacterales or enterococci — a single agent is wrong for the over-fifty, pregnant, immunocompromised or clearly nosocomial patient
- Nitrofurantoin is contraindicated when the creatinine clearance is below 30 mL per minute — inadequate urinary concentration and pulmonary and hepatic toxicity; trimethoprim with an ACE inhibitor, an angiotensin receptor blocker or spironolactone in the elderly risks hyperkalaemia and acute kidney injury within days
- Trimethoprim–sulfamethoxazole, metronidazole, ciprofloxacin and macrolides potentiate warfarin within days through cytochrome P450 inhibition and vitamin-K-cycle disruption — check the anticoagulated patient's INR early and often
- De-escalation is not the same as stopping — a blood culture growing MRSA demands narrowing from piperacillin–tazobactam plus vancomycin to vancomycin (or a beta-lactam if susceptible), not ceasing therapy
- Empirical therapy that is failing at 48 hours demands a structured review — wrong organism, resistant organism, inadequate source control, wrong dose, wrong diagnosis — never an unexamined escalation of spectrum
Meet the patient
A 74-year-old man arrives from a nursing home with 14 hours of fever, confusion and breathlessness, a long-term urinary catheter, and ciprofloxacin three weeks ago. He is in septic shock — lactate 4.2 and a MAP of 57 after fluids — with a right-lower-lobe pneumonia and a nitrite-positive urine. The registrar reaches for ceftriaxone 2 g. Two questions decide whether that single agent is enough: does the regimen cover the likely organism in a healthcare-exposed patient with recent antibiotics? (it may not — escalate to piperacillin-tazobactam for Pseudomonas cover, substituting a carbapenem where ESBL is a specific risk such as known colonisation or prior ESBL infection) and was it given within the hour, with cultures first?[1][9]
Hold those two and stewardship becomes a system rather than a reflex — right drug, right dose, right route, right duration, and de-escalate moment laboratory returns.[1]
References21ShowHide
- [1]Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock Crit Care Med, 2006.PMID 16625125
- [2]Seymour CW, Gesten F, Prescott HC, Friedrich ME, Iwashyna TJ, Phillips GS, et al. Time to Treatment and Mortality during Mandated Emergency Care for Sepsis N Engl J Med, 2017.PMID 28528569
- [3]Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021 Crit Care Med, 2021.PMID 34605781
- [4]Reitz KM, Kennedy J, Li SR, et al. Association Between Time to Source Control in Sepsis and 90-Day Mortality JAMA Surg, 2022.PMID 35830181
- [5]Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America Am J Respir Crit Care Med, 2019.PMID 31573350
- [6]Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America Clin Infect Dis, 2014.PMID 24973422
- [7]Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, et al. Practice guidelines for the management of bacterial meningitis Clin Infect Dis, 2004.PMID 15494903
- [8]Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children Clin Infect Dis, 2011.PMID 21208910
- [9]Tamma PD, Heil EL, Justo JA, et al. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections Clin Infect Dis, 2024.PMID 39108079
- [10]Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists Clin Infect Dis, 2020.PMID 32658968
- [11]Nicolle LE, Gupta K, Bradley SF, Colgan R, DeMuri GP, Drekonja D, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America Clin Infect Dis, 2019.PMID 31506700
- [12]Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america Clin Infect Dis, 2011.PMID 21258094
- [13]By the 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults J Am Geriatr Soc, 2023.PMID 37139824
- [14]O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2 Age Ageing, 2015.PMID 25324330
- [15]Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Clin Infect Dis, 2016.PMID 27080992
- [16]Antimicrobial Resistance Collaborators (Murray CJL, Ikuta KS, Sharara F, et al.). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis Lancet, 2022.PMID 35065702
- [17]Drekonja DM, Filice GA, Greer N, Olson A, MacDonald R, Rutks I, Wilt TJ. Antimicrobial stewardship in outpatient settings: a systematic review Infect Control Hosp Epidemiol, 2015.PMID 25632996
- [18]Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, et al. Augmented Renal Clearance in Critically Ill Patients: A Systematic Review Clin Pharmacokinet, 2018.PMID 29441476
- [19]Cercenado E. [Enterococcus: phenotype and genotype resistance and epidemiology in Spain]. Enferm Infecc Microbiol Clin, 2011.PMID 22305671
- [20]Picard M, Robitaille G, Karam F, et al. Cross-Reactivity to Cephalosporins and Carbapenems in Penicillin-Allergic Patients: Two Systematic Reviews and Meta-Analyses. J Allergy Clin Immunol Pract, 2019.PMID 31170539
- [21]Delzell JE Jr, Lefevre ML. Urinary tract infections during pregnancy. Am Fam Physician, 2000.PMID 10695584